-
The FDA has approved a once-weekly treatment for type 2 diabetes. The new product is a subcutaneously administered extended-release form of the glucagon-like peptide-1 receptor agonist, exenatide. Exenatide extended-release is marketed by Amylin Pharmaceuticals and Alkermes PLC as Bydureon.
-
There do not appear to be any safety issues with the long-term use of statins.
-
-
More than half of patients undergoing non-cardiac surgery and polysomnography had obstructive sleep apnea, which was associated with an increased risk of perioperative complications, including hypoxemia, ICU transfer, and prolonged length of stay.
-
The 12-lead ECG shown above was obtained from a patient with new-onset chest pain. Where is the acute lesion likely to be?
-
-
Attenuated CV Benefits of Clopidogrel in Diabetes; Is A1c Always the Best Game in Town to Monitor Type 2 Diabetes?
-
Results of this year-long intervention trial suggest that an ethanolic extract of curcumin could, together with appropriate dietary and lifestyle changes, play a role in slowing the progression from prediabetes to type 2 diabetes.
-
This paper updates the American Headache Society and American Academy of Neurology guidelines for prevention of episodic migraine that were previously published in 2000.
-
Several commonly used photosensitizing antihypertensive drugs can confer as much as a four-fold increase in the risk of lip cancer when prescribed long-term in non-Hispanic whites.
